Vaxart reported 12-month Phase 2b sentinel COVID-19 cohort data with no vaccine-related serious adverse events; full study topline data are expected in H1 2027.
Q2 FY26 results
Vaxart posted Q2 net loss of USD 13.49 million, narrowing 10% year over year, as revenue fell 32% to USD 27.19 million.
Operating loss improved to USD 13.17 million, while operating expenses dropped 26% to USD 40.36 million.
Government-contract revenue slid 39% to USD 24.26 million, while collaboration revenue turned positive at USD 2.92 million.
R&D expense decreased 32% to USD 33.75 million, due to lower COVID-19 trial, personnel, facilities, preclinical and manufacturing costs.
VXRT•
